title: [Safety of an influenza-split-vaccine in children].
abstract: BACKGROUND
  The aim of this study was to investigate the safety of the split-product influenza vaccine Begrivac(R), containing the recommended virus strains for the influenza season 1998/99.
  
  
  METHODS
  Eighty-three children aged 6 months - 12 years were enrolled in the study.
  
  
  METHODS
  Adverse events (AEs) were reported for up to 21 days after the last immunization. A hemagglutination assay was performed of blood samples taken before and after vaccination.
  
  
  RESULTS
  Only mild (40 %) to moderate and mainly local reactions (redness, swelling, induration and pain) were reported. Seroprotection after the first immunisation was reached against influenza strain A (H1N1) in 75 % of the vaccinees, against strain A (H3N2) in 83 % and against strain B in 33 %. After the second immunisation, 96 % of the population achieved seroprotection against A (H1N1), 100 % against A (H3N2) and 96 % against B.
  
  
  CONCLUSIONS
  The influenza split vaccine is safe and effective in children.
authors.affiliation: Zentrum für Kinderheilkunde, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Schmitt-Grohé
authors.forename: A
authors.initials: A
authors.lastname: Banzhoff
authors.forename: B
authors.initials: B
authors.lastname: Klaassen
authors.forename: S
authors.initials: S
authors.lastname: Zielen
mesh_terms: D000914:Antibodies, Viral / Q000097:blood; D002648:Child; D002675:Child, Preschool; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007223:Infant; D009980:Influenza A virus / Q000276:immunology*; D009981:Influenza B virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control*; D008297:Male; D011446:Prospective Studies
chemical_list: D000914:Antibodies, Viral; D007252:Influenza Vaccines